News Theratechnologies Inc. Nasdaq

Equities

THTX

CA88338H7040

Market Closed - Nasdaq Other stock markets 21:30:00 17/07/2024 BST			5-day change	1st Jan Change
1.535 ^USD	-2.69%		+2.33%	-5.25%

07-10	Theratechnologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2024	CI
07-10	Transcript : Theratechnologies Inc., Q2 2024 Earnings Call, Jul 10, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Theratechnologies: Fiscal Q2 Earnings Snapshot	07-10	AQ
Theratechnologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2024	07-10	CI
Transcript : Theratechnologies Inc., Q2 2024 Earnings Call, Jul 10, 2024	07-10
Theratechnologies Swings to Q2 Profit as Revenue Rises 25%; Confirms FY24 Guidance	07-10	MT
Theratechnologies Brief: Fiscal 2024 revenue guidance confirmed between US$87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 million	07-10	MT
Theratechnologies Brief: Positive net income of US$1 million realized with Adjusted EBITDA of $5.5 million For Q2	07-10	MT
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024	07-10	AQ
Theratechnologies Brief: Q2 Revenue of US$22 million represents 25% growth year-over-year	07-10	MT
Theratechnologies Inc. Provides Earnings Guidance for the Year 2024	07-10	CI
North American Morning Briefing : Powell's Second Day of Remarks Awaited	07-10	DJ
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update	06-26	AQ
Theratechnologies Up Near 5% In US After Hours On Data Related To Its Lead Investigational Peptide Drug Conjugate Candidate	05-23	MT
Theratechnologies Brief: Says Sudocetaxel Zendusortide ASCO 2024 Presentation "Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors"	05-23	MT
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors	05-23	AQ
Theratechnologies Reports on its Annual Meeting of Shareholders	05-09	CI
Theratechnologies Reports on its Annual Meeting of Shareholders	05-09	AQ
Theratechnologies Inc. Announces Frank Holler as Chair of the Board of Directors	05-09	CI
Transcript : Theratechnologies Inc. - Shareholder/Analyst Call	05-09
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting	05-02	AQ
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders	04-15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Theratechnologies Inc. Nasdaq

Equities

THTX

CA88338H7040

Summary

Filters